Changeflow GovPing Pharma & Drug Safety EPO Patent EP4630402A1: Sulfonyl Derivatives as...
Routine Notice Added Final

EPO Patent EP4630402A1: Sulfonyl Derivatives as CCR6 Inhibitors

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP4630402A1 concerning sulfonyl derivatives as CCR6 inhibitors, with F. Hoffmann-La Roche AG listed as the applicant. This publication details chemical compounds and their potential therapeutic applications.

What changed

This document is a publication of a European patent application (EP4630402A1) by F. Hoffmann-La Roche AG, detailing novel sulfonyl derivatives identified as CCR6 inhibitors. The publication includes extensive International Patent Classification (IPC) codes related to organic chemistry and pharmaceutical applications, specifically A61K (Preparations for medical, dental or toilet purposes) and A61P (Specific therapeutic activity of chemical compounds). The designated states indicate broad European coverage for this patent.

As a patent publication, this document does not impose direct regulatory obligations or compliance deadlines on entities. However, it is significant for pharmaceutical companies and drug manufacturers involved in research and development, particularly in areas related to immunology or inflammatory diseases where CCR6 plays a role. Companies should note this patent filing as part of their competitive intelligence and intellectual property landscape monitoring.

Source document (simplified)

← EPO Patent Bulletin

SULFONYL DERIVATIVES AS CCR6 INHIBITORS

Publication EP4630402A1 Kind: A1 Mar 18, 2026

Applicants

F. Hoffmann-La Roche AG

Inventors

BAUTISTA SARMIENTO, Lady Johanna, CALS, Joseph Maria Gerardus Barbara, DE BROUWER, Johanna Hendrika Angelique, DE KIMPE, Vera, DERETEY, Eugen, LAZO MORI, Alger Ayrton, MANDERS, Daan Marten Jorrit, NABUURS, Sander Bernardus

IPC Classifications

C07D 209/42 20060101AFI20240614BHEP C07D 209/46 20060101ALI20240614BHEP C07D 211/96 20060101ALI20240614BHEP C07D 213/64 20060101ALI20240614BHEP C07D 213/81 20060101ALI20240614BHEP C07D 213/82 20060101ALI20240614BHEP C07D 217/24 20060101ALI20240614BHEP C07D 237/14 20060101ALI20240614BHEP C07D 401/12 20060101ALI20240614BHEP C07D 471/04 20060101ALI20240614BHEP C07D 487/04 20060101ALI20240614BHEP C07C 323/22 20060101ALI20240614BHEP A61K 31/4468 20060101ALI20240614BHEP A61P 37/02 20060101ALI20240614BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

SULFONYL DERIVATIVES AS CCR6 INHIBITORS

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4630402A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Intellectual Property
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.